Hemogenyx Pharmaceuticals PLC Announces Macrophage-Directed Therapies Summit Presentation

Rhea-AI Summary

Hemogenyx Pharmaceuticals (LSE:HEMO) has announced its participation in the 6th Macrophage-Directed Therapies Summit in Boston, MA, from October 1-3, 2024. The company will present its work on the proprietary Chimeric Bait Receptor (CBR) platform, an advanced immunotherapy designed to program innate immune cells to combat specific cancers and viral threats.

The presentation will focus on using the CBR platform for treating rare cancers. Dr. Vladislav Sandler, CEO & Co-Founder, emphasized the opportunity to establish Hemogenyx's position in myeloid cell therapies and engage with potential collaborators and investors. This event highlights Hemogenyx's commitment to developing innovative treatments for life-threatening diseases, showcasing its state-of-the-art research capabilities in New York City.

Presentation at Macrophage-Directed Therapies Summit

LONDON, UNITED KINGDOM / ACCESSWIRE / July 29, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to announce its participation in the 6th Macrophage-Directed Therapies Summit ("Summit"), which will be held on October 1-3, 2024, in Boston, MA. The Company will present its work on its proprietary Chimeric Bait Receptor ("CBR") platform.

The Company's CBR platform is an advanced immunotherapy designed to program or redirect innate immune cells, such as macrophages, to eliminate specific types of cancer as well as combat infections from both existing and emerging viral threats. The Company's presentation at the Summit will focus on the use of the CBR platform for the treatment of rare cancers.

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the Summit will provide the Company with an opportunity to further establish its unique position in the emerging field of myeloid cell therapies. It will also allow us to exchange ideas with like-minded cell therapy developers, potential collaborators, and investors."

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on accesswire.com

FAQ

What event is Hemogenyx Pharmaceuticals (HOPHF) participating in on October 1-3, 2024?

Hemogenyx Pharmaceuticals is participating in the 6th Macrophage-Directed Therapies Summit in Boston, MA, from October 1-3, 2024.

What will Hemogenyx Pharmaceuticals present at the Macrophage-Directed Therapies Summit?

Hemogenyx Pharmaceuticals will present its work on the proprietary Chimeric Bait Receptor (CBR) platform, focusing on its use for the treatment of rare cancers.

What is the Chimeric Bait Receptor (CBR) platform developed by Hemogenyx Pharmaceuticals?

The CBR platform is an advanced immunotherapy designed to program or redirect innate immune cells, such as macrophages, to eliminate specific types of cancer and combat viral infections.

Where are Hemogenyx Pharmaceuticals' US operating subsidiaries located?

Hemogenyx Pharmaceuticals' US operating subsidiaries, Hemogenyx Pharmaceuticals and Immugenyx , are located in New York City at the company's state-of-the-art research facility.